Physician profile
Choon K Kim
NPI 1245398874
$4,944.06
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $349 · 2021: $1,079 · 2022: $1,329 · 2023: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568 · Education: $9.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.22 |
| Education | $9.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,975.51 | 2019-2023 | |
| Celgene Corporation | $429.92 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $418.75 | 2021-2023 | |
| Janssen Biotech, INC. | $259.30 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $243.47 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $239.49 | 2020-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.88 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $210.86 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.55 | 2019-2023 | Entyvio |
| Pfizer INC. | $122.31 | 2022-2023 | |
| Genzyme Corporation | $104.59 | 2022-2023 | |
| Braintree Laboratories, INC. | $104.52 | 2019-2023 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $87.40 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $67.67 | 2022-2023 | Dupixent |
| Redhill Biopharma INC. | $46.91 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $41.69 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $36.75 | 2023 | Idacio |
| Allergan, INC. | $35.83 | 2019 | |
| Ironwood Pharmaceuticals, INC | $27.33 | 2019-2022 | |
| Qol Medical, LLC | $26.81 | 2023 | Sucraid |
| Daiichi Sankyo INC. | $23.85 | 2020 | |
| Ardelyx, INC. | $22.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.73 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.26 | 2023 | Cyltezo |
| Boston Scientific Corporation | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Choon Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.